Urogen Pharma (URGN)
(Delayed Data from NSDQ)
$13.22 USD
+0.01 (0.08%)
Updated May 17, 2024 04:00 PM ET
After-Market: $13.25 +0.03 (0.23%) 7:58 PM ET
3-Hold of 5 3
F Value A Growth C Momentum D VGM
Brokerage Reports
Urogen Pharma [URGN]
Reports for Purchase
Showing records 41 - 48 ( 48 total )
Company: Urogen Pharma
Industry: Medical - Biomedical and Genetics
FerGene Spinout Underscores Bladder Cancer Market Potential; 3Q19 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Urogen Pharma
Industry: Medical - Biomedical and Genetics
Stock Price Attrition Appears Overdone; Approaching Critical Value Inflection Points; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Urogen Pharma
Industry: Medical - Biomedical and Genetics
1Q19 Financial Results Reported; UGN-101 Regulatory Filing Approaches; UGN-102 Data Near-Term; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Urogen Pharma
Industry: Medical - Biomedical and Genetics
OLYMPUS Trial Follow-Up Data Reveal Long-Term Treatment Responses; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Urogen Pharma
Industry: Medical - Biomedical and Genetics
Urothelial Carcinoma Expert Conference Call Recap Note
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Urogen Pharma
Industry: Medical - Biomedical and Genetics
Positive Expert Physician Comments Underscore Pipeline Value Proposition; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Urogen Pharma
Industry: Medical - Biomedical and Genetics
FY2018 Financial Results Reported; Spending Higher Than Projected; Reiterate Buy and Modulating Price Target to $75
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Urogen Pharma
Industry: Medical - Biomedical and Genetics
A Next-Generation Leader in Urology; Initiating at Buy and $82 Price Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R